Ali K, Middleton M, Pure E & Rader DJ (2005) Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 97, 922–927.
Asehnoune K, Strassheim D, Mitra S, Kim JY & Abraham E (2004) Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 172, 2522–2529.
Aviram M & Fuhrman B (1998) LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Mol Cell Biochem 188, 149–159.
Beckman JS & Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271, C1424–C1437.
Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM & Pitas RE (1995) Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 96, 2170–2179.
Bokoch GM & Knaus UG (2003) NADPH oxidases: not just for leukocytes anymore! Trends Biochem Sci 28, 502–508.
Borenfreund E & Puerner JA (1985) Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 24, 119–124.
Choi HS, Kim JW, Cha YN & Kim C (2006) A quantitative nitroblue tetrazodium assay for determining intracellular superoxide anion production in phagocytic cells. J Immunoassay Immunochem 27, 31–44.
Colton CA, Brown CM, Cook D, Needham LK, Xu Q, Czapiga M, Saunders AM, Schmechel DE, Rasheed K & Vitek MP (2002) APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging 23, 777–785.
Colton CA, Czapiga M, Snell-Callanan J, Chernyshev ON & Vitek MP (2001) Apolipoprotein E acts to increase nitric oxide production in macrophages by stimulating arginine transport. Biochim Biophys Acta 1535, 134–144.
Colton CA, Needham LK, Brown C, Cook D, Rasheed K, Burke JR, Strittmatter WJ, Schmechel DE & Vitek MP (2004) APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J Neuroimmunol 147, 62–67.
Dietrich M, Hua Y, Block G, Olano E, Packer L, Morrow JD, Hudes M, Abdukeyum G, Rimbach G & Minihane AM (2005) Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans. Lipids 40, 329–334.
Drummen GP, Makkinje M, Verkleij AJ, Op den Kamp JA & Post JA (2004) Attenuation of lipid peroxidation by antioxidants in rat-1 fibroblasts: comparison of the lipid peroxidation reporter molecules cis-parinaric acid and C11-BODIPY(581/591) in a biological setting. Biochim Biophys Acta 1636, 136–150.
Duan H, Lin CY & Mazzone T (1997) Degradation of macrophage ApoE in a nonlysosomal compartment. Regulation by sterols. J Biol Chem 272, 31156–31162.
Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA, Atkinson JB & Linton MF (1997) Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci U S A 94, 4647–4652.
Fernandes MA, Proenca MT, Nogueira AJ, Grazina MM, Oliveira LM, Fernandes AI, Santiago B, Santana I & Oliveira CR (1999) Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. Int J Mol Med 4, 179–186.
Gao R, Stone WL, Huang T, Papas AM & Qui M (2002) The uptake of tocopherols by RAW 264·7 macrophages. Nutr J 1, 2.
Gotoh N, Graham A, Nikl E & Darley-Usmar VM (1993) Inhibition of glutathione synthesis increases the toxicity of oxidized low-density lipoprotein to human monocytes and macrophages. Biochem J 296, Part 1, 151–154.
Hara M, Matsushima T, Satoh H, Iso-o N, Noto H, Togo M, Kimura S, Hashimoto Y & Tsukamoto K (2003) Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Arterioscler Thromb Vasc Biol 23, 269–274.
Hasty AH, Linton MF, Brandt SJ, Babaev VR, Gleaves LA & Fazio S (1999) Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation 99, 2571–2576.
Hatters DM, Peters-Libeu CA & Weisgraber KH (2006) Apolipoprotein E structure: insights into function. Trends Biochem Sci 31, 445–454.
Hayek T, Oiknine J, Brook JG & Aviram M (1994) Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun 201, 1567–1574.
Hernandez-Montes E, Pollard SE, Vauzour D, Jofre-Montseny L, Rota C, Rimbach G, Weinberg PD & Spencer JP (2006) Activation of glutathione peroxidase via Nrf1 mediates genistein's protection against oxidative endothelial cell injury. Biochem Biophys Res Commun 346, 851–859.
Hixson JE & Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31, 545–548.
Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN & Miller GJ (2001) Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 358, 115–119.
Jialal I, Fuller CJ & Huet BA (1995) The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol 15, 190–198.
Jolivalt C, Leininger-Muller B, Bertrand P, Herber R, Christen Y & Siest G (2000) Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Radic Biol Med 28, 129–140.
Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM & Harmony JA (1994) Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 159, 124–139.
Kitagawa K, Matsumoto M, Kuwabara K, Takasawa K, Tanaka S, Sasaki T, Matsushita K, Ohtsuki T, Yanagihara T & Hori M (2002) Protective effect of apolipoprotein E against ischemic neuronal injury is mediated through antioxidant action. J Neurosci Res 68, 226–232.
Lodge JK, Hall WL, Jeanes YM & Proteggente AR (2004) Physiological factors influencing vitamin E biokinetics. Ann N Y Acad Sci 1031, 60–73.
Mardones P, Strobel P, Miranda S, Leighton F, Quinones V, Amigo L, Rozowski J, Krieger M & Rigotti A (2002) Alpha-tocopherol metabolism is abnormal in scavenger receptor class B type I (SR-BI)-deficient mice. J Nutr 132, 443–449.
McCormick CC & Parker RS (2004) The cytotoxicity of vitamin E is both vitamer- and cell-specific and involves a selectable trait. J Nutr 134, 3335–3342.
Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, Murphy MC, Griffin BA & Williams CM (2000) ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 20, 1990–1997.
Mistry MJ, Clay MA, Kelly ME, Steiner MA & Harmony JA (1995) Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. Cell Immunol 160, 14–23.
Miyata M & Smith JD (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14, 55–61.
Naguib YM (1998) A fluorometric method for measurement of peroxyl radical scavenging activities of lipophilic antioxidants. Anal Biochem 265, 290–298.
Pap EH, Drummen GP, Winter VJ, Kooij TW, Rijken P, Wirtz KW, Op den Kamp JA, Hage WJ & Post JA (1999) Ratio-fluorescence microscopy of lipid oxidation in living cells using C11-BODIPY(581/591). FEBS Lett 453, 278–282.
Pepe MG & Curtiss LK (1986) Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 136, 3716–3723.
Peroutka SJ & Dreon DM (2000) The value of genotyping for apolipoprotein E alleles in relation to vitamin E supplementation. Eur J Pharmacol 410, 161–163.
Pham T, Kodvawala A & Hui DY (2005) The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity. Biochemistry 44, 7577–7582.
Pratico D, Lee VM-Y, Trojanowski JQ, Rokach J & Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12, 1777–1783.
Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cacan S, Cohn JS, Christen Y, Schoofs A, Davignon J & Poirier J (2000) Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis 7, 23–37.
Riddell DR, Graham A & Owen JS (1997) Apolipoprotein E inhibits platelet aggregation through the l-arginine:nitric oxide pathway. Implications for vascular disease. J Biol Chem 272, 89–95.
Rimbach G, De Pascual-Teresa S, Ewins BA, Matsugo S, Uchida Y, Minihane AM, Turner R, VafeiAdou K & Weinberg PD (2003) Antioxidant and free radical scavenging activity of isoflavone metabolites. Xenobiotica 33, 913–925.
Rosenblat M & Aviram M (2002) Oxysterol-induced activation of macrophage NADPH-oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: inhibitory role for vitamin E. Atherosclerosis 160, 69–80.
Rosenblat M, Coleman R & Aviram M (2002) Increased macrophage glutathione content reduces cell-mediated oxidation of LDL and atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 163, 17–28.
Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda T, Harada K, Katsuki M, Yazaki Y & Yamada N (1995) Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest 95, 469–476.
Smith JD, Miyata M, Ginsberg M, Grigaux C, Shmookler E & Plump AS (1996) Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J Biol Chem 271, 30647–30655.
Song Y, Stampfer MJ & Liu S (2004) Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141, 137–147.
Stannard AK, Riddell DR, Sacre SM, Tagalakis AD, Langer C, von Eckardstein A, Cullen P, Athanasopoulos T, Dickson G & Owen JS (2001) Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Biol Chem 276, 46011–46016.
Talmud PJ, Stephens JW, Hawe E, Demissie S, Cupples LA, Hurel SJ, Humphries SE & Ordovas JM (2005) The significant increase in cardiovascular disease risk in APOEɛ4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet 69, 613–622.
Tamaoka A, Miyatake F, Matsuno S, et al. (2000) Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology 54, 2319–2321.
Wang-Iverson P, Gibson JC & Brown WV (1985) Plasma apolipoprotein secretion by human monocyte-derived macrophages. Biochim Biophys Acta 834, 256–262.
Yamada N, Inoue I, Kawamura M, et al. (1992) Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 89, 706–711.
Yoshida H, Hasty AH, Major AS, Ishiguro H, Su YR, Gleaves LA, Babaev VR, Linton MF & Fazio S (2001) Isoform-specific effects of apolipoprotein E on atherogenesis: gene transduction studies in mice. Circulation 104, 2820–2825.
Yoshida T (1996) Determination of reduced and oxidized glutathione in erythrocytes by high-performance liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Biomed Appl 678, 157–164.
Zeleny M, Swertfeger DK, Weisgraber KH & Hui DY (2002) Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation. Biochemistry 41, 11820–11823.
Zhou J, Struthers AD & Lyles GA (1999) Differential effects of some cell signalling inhibitors upon nitric oxide synthase expression and nuclear factor-kappaB activation induced by lipopolysaccharide in rat aortic smooth muscle cells. Pharmacol Res 39, 363–373.